Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Real Estate
  • Technology
  • Entertainment
  • Health
ncarol.com

TransEnterix Announces Closing of $31.25 Million Registered Direct Offering of Common Stock
ncarol.com/10095861

Trending...
  • USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced registered direct offering of 25,000,000 shares of its common stock. The offering was priced at a purchase price per share of $1.25, for gross proceeds of approximately $31.25 million.

TransEnterix intends to use the net proceeds from the offering for general corporate purposes, including working capital.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

A shelf registration statement on Form S-3 (File No. 333-236200) relating to the registered direct offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on February 10, 2020. The offering of the shares of common stock was made only by means of a prospectus supplement and accompanying prospectus that forms a part of the registration statement. Electronic copies of the final prospectus supplement and the accompanying prospectus have been filed with the SEC and may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing placements@hcwco.com or at the SEC's website at http://www.sec.gov. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

More on ncarol.com
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME

Balance Sheet Update

The Company believes that cash on hand, proceeds from the ATM Offering and the Series C and Series D Warrant exercises, as well as the proceeds from this offering will be sufficient to fund operations into the fourth quarter of 2022.

About TransEnterix

At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance® Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: https://Senhance.com/. Now available for sale in the US, the EU, Japan, Russia, and select other countries. For a complete list of indications for use, please visit: https://www.transenterix.com/indications-for-use/.

More on ncarol.com
  • Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month
  • Indianapolis Criminal Defense Firm Rigney Law LLC Relaunches Criminal Law Podcast "Tales from the Brown Desk"
  • 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Advantage Newspaper Consultants Celebrates 30 Years of Serving the Newspaper Industry

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the intended use of proceeds from the registered direct offering and our expected cash reach. These statements involve significant risks and uncertainties, including those discussed in the prospectus supplement related to the offering and in our annual report on Form 10-K for the fiscal year ended December 31, 2019 and our other filings with the SEC. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. We are providing this information as of January 14, 2021. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements, except as required by law..
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Shuttle Buddy Announces Amazon Partnership to Launch Workforce Express in North Carolina
  • Inlow Upholstery Helps Cleveland County Homeowners Refresh Furniture with Custom Upholstery
  • Birthstones Are Having a 2026 Moment. KayeDinero's "Aquamarine" Began With Her Grandmother
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
  • A Dependable Marks 29 Years of Home Remodeling and General Contracting in the Charlotte Region
  • Living Waters Inc to Host Mental Health Summit
  • Black Diamond Sport & Entertainment Group Signs Defensive End Camar Kyle for Representation
  • Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
  • The Marcus Harris Foundation Awarded Grant From Macon County Community Foundation
  • Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
  • Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
  • Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
  • Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
  • "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
  • NASA Spotlighted the 2026 Harvest Moon. KayeDinero Filmed It Over Asheville
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • Yacht Captain Transforms Life Of Adventure Into A Children's Series Celebrating Courage & Kindness
_catLbl0 _catLbl1

Popular on ncarol.com

  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 177
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 160
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 150
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 133
  • MommyAndMe.club Expands Parent-Child Class Directory to All 50 States and Washington, D.C - 111
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB) - 110
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 109
  • Badanamu and Friends Live Brings Hit Animated Series to Stages Across the United States - 104
  • ChargeOn Announces Conversational Payment Management Solution - 103
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide

Similar on ncarol.com

  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Advantage Newspaper Consultants Celebrates 30 Years of Serving the Newspaper Industry
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute